Lymphangioleiomyomatosis

This phase 1 trial is testing the long-term safety of imatinib (Gleevec), a drug already approved for leukemia, in 20 women with lymphangioleiomyomatosis (LAM), a rare cystic lung disease. Participants will take either imatinib or a placebo twice daily for 6 months, with regular …

This study tests whether a nebulizer or a standard inhaler delivers albuterol better to improve breathing in women with LAM, a rare lung disease. About 100 women with reduced lung function will stay overnight for 3 days to try each method. The goal is to see which approach opens …

This study aims to understand how lymphangioleiomyomatosis (LAM) damages the lungs at the cellular and genetic level. Researchers will follow up to 2,000 participants, including women with LAM and healthy volunteers, using advanced imaging and lab tests. The goal is to find the p…

Researchers in France are building a national registry of people with lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women. The registry aims to estimate how many people in France have LAM, gather demographic details, and record when and how the disease i…

This study is building a large collection of blood, DNA, and tissue samples along with health records from up to 5,000 people with tuberous sclerosis complex (TSC) or a related condition called lymphangioleiomyomatosis. Participants can give blood or cheek swab samples and allow …

This study collects information from pregnant women with Tuberous Sclerosis Complex (TSC) or Lymphangioleiomyomatosis (LAM) and their babies. Researchers will monitor medication use, side effects, pregnancy complications, and mental health after birth. The goal is to better under…

This study looks at tiny particles called extracellular vesicles in the blood of women with a rare lung disease called LAM. Researchers want to see if these particles can act as biomarkers to show how the lungs are affected. The study will compare women with different forms of LA…